Mon-Fri 9am-5pm (EST)
Mike Hoerres brings more than 25 years of experience generating revenue and building new markets in the life sciences industry to his role as CEO of Cernostics. In his role Mike leads overall strategic direction for the company, and applies his passion for improving healthcare through genomic and proteomic technologies to the company. Previously Mike was Principal at Geisinger Ventures, the venture arm affiliated with Geisinger Health System, a leading integrated healthcare delivery organization in the United States. In this role Mike led partnering activities with life science companies focused on diagnostic development and personalized medicine. Geisinger's focus on innovation in personalized healthcare led to an investment in Cernostics, after which time Mike assumed the role of CEO. Mike also served in a variety of sales, marketing and business development roles at Affymetrix, Incyte Genomics, Source MDx, and Stratagene (acquired by Agilent).
Mike currently serves on the Board of Directors of Pennsylvania Bio, Pennylvania's largest life science trade organization supporting the life science community through advocacy, enterprise support and collaboration. Mike holds a BS in biochemistry of University of Wisconsin and a Master of Science in molecular immunology from San Diego State University.
Dr. Critchley-Thorne is responsible for research and development of novel diagnostic tests based on Cernostics' proprietary TissueCypher™ platform. She is a cancer immunologist with expertise in molecular and functional profiling of patient samples and was previously a Senior Scientist at Cellumen, Inc. in the Patient Sample Profiling Program, responsible for the collaborative project on breast cancer diagnostics with the Mayo Clinic.
Dr. Critchley-Thorne completed post-doctoral training at Stanford University in the Department of Medicine, Division of Hematology. Her research focused on functional profiling using multiplexed fluorescence immune biomarker analysis and also gene expression profiling of the immune system in cancer patient samples to identify mechanisms of tumor-induced immune dysfunction. She earned her PhD in Oncology from Imperial College, London, UK where her thesis was on recombinant E. coli as vectors for cancer prodrug therapy and immunotherapy.
Mon-Fri 9am-5pm (EST)